An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements

This article has no abstract
Epistemonikos ID: 1abfb4854ad0df423eaad026284507943530a49d
First added on: Feb 17, 2025